Cost Per Responder of Apremilast Versus Infliximab Biosimilar, Etanercept, Adalimumab, Ustekinumab and Secukinumab in Patients with Moderate to Severe Psoriasis in Spain

Saved in:
Bibliographic Details
Published inValue in health Vol. 19; no. 7; p. A569
Main Authors Martinez-Sesmero, JM, Schoendorff, C, Caloto, T
Format Journal Article
LanguageEnglish
Published 01.11.2016
Subjects
Internal Medicine
Online AccessGet full text

Cover

More Information
ISSN:1098-3015
DOI:10.1016/j.jval.2016.09.1285